Colloidal particles ranging in size between 10 & 1000 nm are known as nanoparticles.
SLNs are new generation of submicron sized lipid emulsion where the liquid lipid(oil) has been substituted by a solid lipid.
Example: Capture - Dior
VIP Service Call Girls Sindhi Colony 📳 7877925207 For 18+ VIP Call Girl At Th...
Solid lipid nanoparticle
1. Department of Pharmacy (Pharmaceutics)Department of Pharmacy (Pharmaceutics) || Sagar savaleSagar savale
Mr. Sagar Kishor SavaleMr. Sagar Kishor Savale
Department of Pharmaceutics
avengersagar16@gmail.com
2015-016
2. Content:
History
Introduction
Advantage of SLNs over Polymeric nanoparticles
Methods of Preparation
Sterilization of SLNs
Analytical characterization of SLNs
Applications of SLNs
Conclusion
References
204/28/16 Sagar Savale
4. Introduction:
Colloidal particles ranging in size between 10 & 1000 nm are
known as nanoparticles.
SLNs are new generation of submicron sized lipid emulsion
where the liquid lipid(oil) has been substituted by a solid lipid.
Example: Capture - Dior
404/28/16 Sagar Savale
5. Advantages of SLNs:
Control & target drug release
Increased drug stability
High & enhanced drug content
Feasible for carrying both lipophilic & hydrophilic drug
Excellent biocompatibility
Water based technology
Easy to scale up & sterlize
Avoid RES
504/28/16 Sagar Savale
6. Disadvantages:
Drug Loading capacity is limited
High water content
High pressure induce drug degradation
Coexistences of several colloidal species
Lipid crystallization & drug incorporation
- supercooled melts
- gelation phenomenon
Drug expulsion
604/28/16 Sagar Savale
8. NLC the more intelligent system….
804/28/16 Sagar Savale
9. Advantages of SLNs over polymeric NPs
Polymeric
Nanoparticles
Solid Lipid
Nanoparticles
Residual contamination Avoid residual contamination
Possible toxicity problems No toxicity problems
Expensive production & a lack of
large scale production method
Cost effective methods are
available
Lack of suitable sterilization
method
Feasible sterilization method
available
Not stable as compared to SLNs SLNs formulation stable for even
three years have been developed
904/28/16 Sagar Savale
10. SLNs preparation:
General ingredients include solid lipid, emulsifier & water
Lipid contains triglycerides, partial glycerides, fatty acids,
steroids, waxes
Combination of emulsifier might prevent particle
agglomeration
Emulsifier include soybean lecithin, egg lecithin,
poloxmer etc.
1004/28/16 Sagar Savale
11. Method of preparation:
High pressure homogenization
- Hot homogenization
- Cold homogenization
Ultrasonication
Solvent emulsification/evaporation
Micro emulsion
Using Supercritical Fluid
By Spray drying
1104/28/16 Sagar Savale
12. Hot Homogenization
Melting of the lipid & dissolving/dispersing of the drug in the lipid
Dispersing of the drug loaded lipid in a hot aqueous surfactant mixture.
Premix using a stirrer to form a coarse preemulsion
High pressure homogenization at a temperature above the lipid M.P.
Hot O/W nanoemulsion
Solid Lipid Nanoparticles
Disadvantages: 1) temperature induce drug degradation
2) partioning effect
3) complexity of the crystallization
1204/28/16 Sagar Savale
13. Cold Homogenization
Melting of lipid & dissolving/dispersing of the drug in the lipid
Solidification of the drug loaded lipid in liquid nitrogen or dry ice
Grinding in a powder mill
Dispersing the powder in a aqueous surfactant dispersion medium
High pressure homogenization at room temperature or below.
Solid Lipid Nanoparticles
Disadvantages: 1) Larger particle sizes & broader size distribution
2) does not avoid thermal exposure but minimizes it
1304/28/16 Sagar Savale
14. Ultrasonication:
Adv. :
1) Equipment used is very common
2) No temperature induced drug degradation
Disadv.:
1) Potential metal contamination
2) Broader particle size distribution
1404/28/16 Sagar Savale
15. Solvent emulsification:
Lipophilic material is dissolved in a water immiscible
organic solvent (e.g.cyclohexane) that is emulsified in an
aqueous phase.
Upon evaporation of solvent, a nanoparticle dispersion is
formed by ppt of lipid in aq. Medium.
Adv.: Avoidance of any thermal stress
Disadv.: use of organic solvents.
1504/28/16 Sagar Savale
16. Using Microemulsion:
Preparation by stirring optically transparent mixture at 65-
70o
c composed of a low melting fatty acid, emulsifier,
coemulsifier & water.
This hot microemulsion dispersed in cold water (2-3o
c) &
stirring.
1604/28/16 Sagar Savale
17. By using Supercritical fluid
Can be prepared by Rapid Expansion of Supercritical Carbon
dioxide solution methods(RESS)
Adv.: 1) Solvent less processing.
By Spray drying method
Alternative to lyophilization
Disadv.:
1) particle aggregation due to high temp., shear forces
& partial melting of particles.
2) Recommended use of lipid with M.P. >700
c for
spray drying.
1704/28/16 Sagar Savale
18. Sterilization of SLNs
For parentral & ocular administration SLNs must be
sterile.
For lecithin stabilized SLNs autoclaving is possible & it is
not possible for sterically stabilized polymers.
Physical stability during autoclave can not be stated, it
depends on composition.
SLN dispersion can also be sterilized by filtration
1804/28/16 Sagar Savale
19. Characterization of SLNs:
[I] Measurement of particle size
Photon correlation spectroscopy
Transmission electron microscopy
Scanning electron microscopy
Field Flow Fractionation (FFF)
X-ray diffraction
1904/28/16 Sagar Savale
20. [II] Measurement of Zeta Potential
Allows predictions about the storage stability of colloidal dispersion
Zeta potential under 30 mV are required for full electrostatic
stabilization.
[III] Molecular weight
Gel chromatography
Atomic force microscopy
[IV] Surface element analysis
X-ray photoelectron spectroscopy
Electrophoresis
Laser doppler anaemometry
XRD
DSC 2004/28/16 Sagar Savale
21. [V] DENSITY
Helium compression pychnometry
Contact angle measurement
[VI] Molecular analysis
H-NMR
Infra red analysis
[VI] Measurement of Crystallinity, Lipid modification
DSC & X-ray scattering used to investigate status of lipid
2104/28/16 Sagar Savale
22. [VII] Coexistence of additional colloidal structure
NMR & ESR used for this purpose
2204/28/16 Sagar Savale
24. oRaL SLN iN aNtituBeRCuLaR tHeRaPY
Anti-tubercular drugs such as rifampicin, isoniazide, loaded
SLNs able to decrease dosing frequency
SLN aS a GeNe VeCtoR CaRRieR
Several recent reports of SLN carrying genetic materials such as
DNA, plasmid DNA, & other nucleic acid.
2404/28/16 Sagar Savale
25. Major challenges where nanotech is
needed in cancer therapy
Cancer comes from our cells – domestic terrorist!
Cancers are different from patient to patient
Cancers continue to change as they grow
2504/28/16 Sagar Savale
26. Challenge #1: Cancer comes from our cells –
domestic terrorist!
Bacteria & viruses = easy to
spot
Cancer = difficult to detect,
difficult to treat
2604/28/16 Sagar Savale
27. Challenge #2: Cancers are different from
patient to patient
Each tumor is like a salad from a salad bar
They all have a unique combination of ingredients (DNA
errors)
2704/28/16 Sagar Savale
28. Challenge #3: Cancers continue to change
as they grow
Challenge #3: Cancers continue to change as they grow
If a tumor is detected too late, it has probably already won
2804/28/16 Sagar Savale
30. Tumor Mass
SLNs attack blood vesicles
which nourish metastatic tumors
04/28/16 Sagar Savale 30
31. WHY SLN FOR ANTICANCER THERAPY ?
Improved stability of cytotoxic compounds by SLN
encapsulation
Improved pharmacokinetics and drug biodistribution by SLN
Significant anticancer activity of SLN-encapsulated cytotoxic
drug.
3104/28/16 Sagar Savale
32. Changes in biodistribution of antiCanCer
drugs delivered by sln
Drug Organs with increased drug
concentration delivered by SLN
Idarubicin Blood, brain
Etoposide Blood, brain, tumor, liver, lung, spleen,
kidney, bone
Doxorubicin Blood, brain
Camptothecin Blood, brain, liver, lung, spleen, kidney,
heart
3204/28/16 Sagar Savale
33. Potential of sln in brain targeting
SLNs taken up readily by the brain due to their lipidic nature.
high potential to treat brain cancer.
New formulations of neuroactive drugs into SLN are expected
to improve their pharmacokinetic profile.
3304/28/16 Sagar Savale
34. References:
Muller R.H., Mader K., Gohla S. “ Solid lipid nanoparticles
(SLN) for controlled drug delivery – a review of the state of
art” European journal of Pharmaceutics & Biopharmaceutics,
50 (2000) 161-177
Kaur I.P., Bhandari R., Bhandari S., Kakkar V. “ Potential of
Solid lipid nanoparticles in brain targeting” Journal of
Controlled release, 127 (2008) 97-109
Wong H.L., Bendayn R., Rauth A.M., Yongqiang L., Xiao
Y.W. “ Chemotherapy with anticancer drugs encapsulated in
solid lipid nanoparticles’’ Advanced drug delivery reviews, 59
(2007) 491-504
3404/28/16 Sagar Savale
35. Mehnert W., Mader K. “ Solid lipid nanoparticles Production,
characterization and applications” Advanced drug delivery
reviews, 47 (2001) 165-196.
Schwarz C., Mehnert W., Lucks J.S., Muller R.H. “ Solid lipid
nanoparticles (SLN) for controlled drug delivery Production,
characterization and sterilization” Journal of controlled release
30 (1994) 83-96.
Gasco M.R. “ Lipid nanoparticles: perspectives and challenges”
Advanced drug delivery reviews, 59 (2007) 377-378.
3504/28/16 Sagar Savale